Trevena Inc. (TRVN) 5.39 $TRVN
Trevena CEO to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Tue Apr 01, 3:01PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 2:20 p.m. ET in New York City.
Trevena Appoints Robert Prachar as Senior Vice President, Commercial and Corporate Strategy
Business Wire - Tue Apr 01, 6:00AM CDT
Trevena, Inc. (NASDAQ:TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the appointment of Robert Prachar to the newly created position of Senior Vice President, Commercial and Corporate Strategy, effective immediately. Mr. Prachar, who has served as a full-time consultant for the Company since August 2013, brings over 20 years of commercial leadership experience in the life sciences industry.
Nasdaq stocks posting largest percentage increases
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Trevena Reports Full Year 2013 Financial Results
Business Wire - Thu Mar 20, 6:00AM CDT
Trevena, Inc. (NASDAQ:TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced financial results for the year ended December 31, 2013.
Trevena to Host Conference Call on March 20th to Discuss Full Year 2013 Financial Results and Recent Highlights
Business Wire - Thu Mar 13, 3:16PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced that it will host a conference call on Thursday, March 20, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2013.
Trevena Announces Partial Exercise of Underwriters' Overallotment Option
Business Wire - Thu Mar 06, 4:04PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that the underwriters for its initial public offering of common stock have partially exercised their over-allotment option and purchased an additional 270,449 shares. The additional shares were sold at the public offering price of $7.00 per share, before underwriting discounts. The closing occurred on March 6, 2014, bringing the total number of shares sold by Trevena in the initial public offering to 9,520,499 shares and total gross proceeds, before deducting underwriting discounts and commissions and offering expenses, to approximately $67 million.
Trevena CEO to Present at the Barclays Global Healthcare Conference
Business Wire - Wed Mar 05, 6:00AM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company and leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 11, 2014 at 10:45 a.m. ET in Miami, FL.
Trevena, Inc. [TRVN] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Feb 18, 9:00AM CST
What:
Trevena concludes IPO at USD7.00 per share
M2 - Thu Feb 06, 4:42AM CST
US-based pharmaceutical company Trevena Inc (NasdaqGS:TRVN) reported on Wednesday the completion of its initial public offering of 9.25m shares of common stock.
Trevena Announces Closing of Initial Public Offering
Business Wire - Wed Feb 05, 3:05PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the closing of its initial public offering of 9,250,000 shares of common stock at an initial public offering price of $7.00 per share.
Trevena Initiates Clinical Development of TRV734, a Novel Biased Ligand for Moderate to Severe Pain
Business Wire - Wed Feb 05, 6:00AM CST
Trevena, Inc. (NASDAQ:TRVN), a clinical-stage pharmaceutical company and leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the initiation of its first Phase 1 trial for TRV734, a novel drug candidate in development as an orally administered treatment for moderate to severe acute and chronic pain. TRV734 is being developed to optimize analgesia while minimizing on-target gastrointestinal and respiratory effects through its novel biased ligand mechanism at the mu-opioid receptor. TRV734 takes advantage of the same receptor specificity mechanism as does Trevena's Phase 2 clinical candidate, TRV130, an intravenous mu-opioid G protein biased ligand being developed for acute postoperative pain.
Trevena to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 6:00AM CST
Trevena, Inc. (NASDAQ:TRVN), a clinical stage pharmaceutical company and a leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., president and chief executive officer of Trevena, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 11:00 a.m. ET in New York City.
IPO roundup: 6 companies go public Friday
By The Associated Press - AP - Fri Jan 31, 5:32PM CST
Six companies made their stock market debuts Friday as the IPO market revs up in 2014. Last year the market for initial public offerings boomed as stock markets rose, with major debuts from hotel owner Hilton Worldwide Holdings Inc., which raised $2.35 billion, and online messaging service Twitter Inc., which raised $2.1 billion.
Trevena Announces Pricing of Initial Public Offering of 9,250,000 Shares of Common Stock
Business Wire - Fri Jan 31, 5:30AM CST
Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its initial public offering of 9,250,000 shares of common stock at a price of $7.00 per share. Trevena previously announced that the number of shares in the offering was 8,500,000. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "TRVN" on January 31, 2014. In addition, Trevena has granted the underwriters a 30-day option to purchase up to 1,387,500 additional shares of common stock from Trevena at the initial public offering price. The offering is expected to close on February 5, 2014, subject to customary closing conditions.
Trevena Announces Pricing of Initial Public Offering
Business Wire - Thu Jan 30, 4:35PM CST
Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its initial public offering of 8,500,000 shares of common stock at a price of $7.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "TRVN" on January 31, 2014. In addition, Trevena has granted the underwriters a 30-day option to purchase up to 1,275,000 additional shares of common stock from Trevena at the initial public offering price. The offering is expected to close on February 5, 2014, subject to customary closing conditions.
Trevena Announces Dosing of First Patient in Phase 2b BLAST-AHF Trial of TRV027 for Acute Heart Failure
Business Wire - Thu Jan 09, 5:59AM CST
Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center Phase 2b trial of TRV027 in patients with acute heart failure (AHF). TRV027 is a novel beta-arrestin biased ligand of the angiotensin II type 1 receptor that is being developed as a first-line intravenous treatment in combination with standard diuretic therapy for AHF patients. Trevena has granted Forest Laboratories (NYSE:FRX) an exclusive option to license TRV027 under the companies' May 2013 Option and Licensing Agreements.
Trevena Appoints Francois Nader, MD, to its Board of Directors
Business Wire - Wed Jan 08, 5:59AM CST
Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today that Francois Nader, MD, president and chief executive officer of NPS Pharmaceuticals, Inc. has joined its Board of Directors. Dr. Nader is an industry leader with over 30 years of experience in the healthcare sector.
Trevena CEO to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Tue Apr 01, 3:01PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 2:20 p.m. ET in New York City.
Trevena Appoints Robert Prachar as Senior Vice President, Commercial and Corporate Strategy
Business Wire - Tue Apr 01, 6:00AM CDT
Trevena, Inc. (NASDAQ:TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the appointment of Robert Prachar to the newly created position of Senior Vice President, Commercial and Corporate Strategy, effective immediately. Mr. Prachar, who has served as a full-time consultant for the Company since August 2013, brings over 20 years of commercial leadership experience in the life sciences industry.
Nasdaq stocks posting largest percentage increases
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Trevena Reports Full Year 2013 Financial Results
Business Wire - Thu Mar 20, 6:00AM CDT
Trevena, Inc. (NASDAQ:TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced financial results for the year ended December 31, 2013.
Trevena to Host Conference Call on March 20th to Discuss Full Year 2013 Financial Results and Recent Highlights
Business Wire - Thu Mar 13, 3:16PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced that it will host a conference call on Thursday, March 20, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2013.
Trevena Announces Partial Exercise of Underwriters' Overallotment Option
Business Wire - Thu Mar 06, 4:04PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that the underwriters for its initial public offering of common stock have partially exercised their over-allotment option and purchased an additional 270,449 shares. The additional shares were sold at the public offering price of $7.00 per share, before underwriting discounts. The closing occurred on March 6, 2014, bringing the total number of shares sold by Trevena in the initial public offering to 9,520,499 shares and total gross proceeds, before deducting underwriting discounts and commissions and offering expenses, to approximately $67 million.
Trevena CEO to Present at the Barclays Global Healthcare Conference
Business Wire - Wed Mar 05, 6:00AM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company and leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 11, 2014 at 10:45 a.m. ET in Miami, FL.
Trevena, Inc. [TRVN] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Feb 18, 9:00AM CST
What:
Trevena concludes IPO at USD7.00 per share
M2 - Thu Feb 06, 4:42AM CST
US-based pharmaceutical company Trevena Inc (NasdaqGS:TRVN) reported on Wednesday the completion of its initial public offering of 9.25m shares of common stock.
Trevena Announces Closing of Initial Public Offering
Business Wire - Wed Feb 05, 3:05PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the closing of its initial public offering of 9,250,000 shares of common stock at an initial public offering price of $7.00 per share.
Trevena Initiates Clinical Development of TRV734, a Novel Biased Ligand for Moderate to Severe Pain
Business Wire - Wed Feb 05, 6:00AM CST
Trevena, Inc. (NASDAQ:TRVN), a clinical-stage pharmaceutical company and leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the initiation of its first Phase 1 trial for TRV734, a novel drug candidate in development as an orally administered treatment for moderate to severe acute and chronic pain. TRV734 is being developed to optimize analgesia while minimizing on-target gastrointestinal and respiratory effects through its novel biased ligand mechanism at the mu-opioid receptor. TRV734 takes advantage of the same receptor specificity mechanism as does Trevena's Phase 2 clinical candidate, TRV130, an intravenous mu-opioid G protein biased ligand being developed for acute postoperative pain.
Trevena to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 6:00AM CST
Trevena, Inc. (NASDAQ:TRVN), a clinical stage pharmaceutical company and a leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., president and chief executive officer of Trevena, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 11:00 a.m. ET in New York City.
IPO roundup: 6 companies go public Friday
By The Associated Press - AP - Fri Jan 31, 5:32PM CST
Six companies made their stock market debuts Friday as the IPO market revs up in 2014. Last year the market for initial public offerings boomed as stock markets rose, with major debuts from hotel owner Hilton Worldwide Holdings Inc., which raised $2.35 billion, and online messaging service Twitter Inc., which raised $2.1 billion.
Trevena Announces Pricing of Initial Public Offering of 9,250,000 Shares of Common Stock
Business Wire - Fri Jan 31, 5:30AM CST
Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its initial public offering of 9,250,000 shares of common stock at a price of $7.00 per share. Trevena previously announced that the number of shares in the offering was 8,500,000. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "TRVN" on January 31, 2014. In addition, Trevena has granted the underwriters a 30-day option to purchase up to 1,387,500 additional shares of common stock from Trevena at the initial public offering price. The offering is expected to close on February 5, 2014, subject to customary closing conditions.
Trevena Announces Pricing of Initial Public Offering
Business Wire - Thu Jan 30, 4:35PM CST
Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its initial public offering of 8,500,000 shares of common stock at a price of $7.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "TRVN" on January 31, 2014. In addition, Trevena has granted the underwriters a 30-day option to purchase up to 1,275,000 additional shares of common stock from Trevena at the initial public offering price. The offering is expected to close on February 5, 2014, subject to customary closing conditions.
Trevena Announces Dosing of First Patient in Phase 2b BLAST-AHF Trial of TRV027 for Acute Heart Failure
Business Wire - Thu Jan 09, 5:59AM CST
Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center Phase 2b trial of TRV027 in patients with acute heart failure (AHF). TRV027 is a novel beta-arrestin biased ligand of the angiotensin II type 1 receptor that is being developed as a first-line intravenous treatment in combination with standard diuretic therapy for AHF patients. Trevena has granted Forest Laboratories (NYSE:FRX) an exclusive option to license TRV027 under the companies' May 2013 Option and Licensing Agreements.
Trevena Appoints Francois Nader, MD, to its Board of Directors
Business Wire - Wed Jan 08, 5:59AM CST
Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today that Francois Nader, MD, president and chief executive officer of NPS Pharmaceuticals, Inc. has joined its Board of Directors. Dr. Nader is an industry leader with over 30 years of experience in the healthcare sector.
